- Email: [email protected]
neu overexpression for cancer therapy”
Drug Resistance Updates 6 (2003) 295–296
Erratum
Erratum to “Strategies to target HER2/neu overexpression for cancer therapy” [Drug Resistance Updates 6(3) (2003)129–1361]夽 Jin-Shing Chen a,b , Kengli Lan a , Mien-Chie Hung a,∗ a
b
Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 79, Houston, TX 77030, USA Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, Taiwan
The Publisher regrets that in the printed and on-line versions of the above article, Fig. 1 contained two errors. The correct version of Fig. 1 is reprinted below:
夽
doi of original article: 10.1016/S1368-7646(03)00040-2. Corresponding author. Tel.: +1-713-792-3668; fax: +1-713-794-0209. E-mail address: [email protected] (M.-C. Hung).
∗
1368-7646/$ – see front matter © 2003 Elsevier Ltd. All rights reserved. doi:10.1016/j.drup.2003.08.002
296
J.-S. Chen et al. / Drug Resistance Updates 6 (2003) 295–296
Fig. 1. Targeting strategies in HER2/neu-overexpressing cancer cells. From cell surface to the nucleus, overexpression of HER2/neu can be suppressed by: (1) exogenous blocking antibodies such as trastuzumab; (2) antibodies disrupting ligand-activated signaling and heterodimerization of HER2/neu such as 2C4; (3) immunological responses elicited by anti-HER2/neu vaccines; (4) tyrosine kinase inhibitors of HER2/neu and/or other EGFR receptors; (5) intracellular single-chain antibodies in ER; (6) transcription suppressors of HER2/neu promoter such as E1A; and (7) antisense oligonucleotides or ribozymes.
Erratum
Erratum to “Strategies to target HER2/neu overexpression for cancer therapy” [Drug Resistance Updates 6(3) (2003)129–1361]夽 Jin-Shing Chen a,b , Kengli Lan a , Mien-Chie Hung a,∗ a
b
Department of Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd. Unit 79, Houston, TX 77030, USA Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, Taiwan
The Publisher regrets that in the printed and on-line versions of the above article, Fig. 1 contained two errors. The correct version of Fig. 1 is reprinted below:
夽
doi of original article: 10.1016/S1368-7646(03)00040-2. Corresponding author. Tel.: +1-713-792-3668; fax: +1-713-794-0209. E-mail address: [email protected] (M.-C. Hung).
∗
1368-7646/$ – see front matter © 2003 Elsevier Ltd. All rights reserved. doi:10.1016/j.drup.2003.08.002
296
J.-S. Chen et al. / Drug Resistance Updates 6 (2003) 295–296
Fig. 1. Targeting strategies in HER2/neu-overexpressing cancer cells. From cell surface to the nucleus, overexpression of HER2/neu can be suppressed by: (1) exogenous blocking antibodies such as trastuzumab; (2) antibodies disrupting ligand-activated signaling and heterodimerization of HER2/neu such as 2C4; (3) immunological responses elicited by anti-HER2/neu vaccines; (4) tyrosine kinase inhibitors of HER2/neu and/or other EGFR receptors; (5) intracellular single-chain antibodies in ER; (6) transcription suppressors of HER2/neu promoter such as E1A; and (7) antisense oligonucleotides or ribozymes.